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Should the targeted value of the
phosphate be reviewed in the
normal range from the viewpoint
of vascular calcification?
To the Editor: In patients with chronic kidney disease stage
(CKD) 5D, the Kidney Disease: Improving Global Outcomes
(KDIGO) guidelines suggest lowering elevated phosphorus
(P) levels toward the normal range. In patients on dialysis,
multiple studies from different parts of the world have shown
that higher levels of serum P have been associated with an
increased relative risk (RR) of mortality. The inﬂection point
or range in which P level becomes signiﬁcantly associated
with increased all-cause mortality varies among studies for
the reasons cited above: 5.0–5.5mg/dl (1.6–1.8mmol/l),
45.5mg/dl (41.8mmol/l), 6.0–7.0mg/dl (1.9–2.3mmol/l),
and 46.5mg/dl (42.1mmol/l). However, most of these
multiple studies did not show signiﬁcant differences between
the normal range and moderately high P levels in mortality.1
As per the KDOQI Clinical Practice Guidelines, serum levels
of P should be maintained between 3.5 and 5.5mg/dl
(1.13 and 1.78mmol/l) in CKD patients with kidney failure
(stage 5). These values were set from the viewpoint of
mortality. The cross-sectional study that met the inclusion
criteria evaluated the association of serum P levels with
extraskeletal outcomes. In the KDOQI Clinical Practice
Guidelines, a reference serum P level range of 4.6–5.5mg/dl
(1.49–1.78mmol/l) is stated, and the RR of mortality is
suggested to increase with serum P levels 46.5mg/dl
(2.10mmol/l).2
If the management-targeted value of P level is set from the
view of not mortality but vascular and valvular calciﬁcation, it
should be set lower.
We reported the associations of serum P concentrations
with coronary artery calciﬁcation by 16-slice multislice
computer tomography (MSCT) in ESRD patients. For this,
we recruited 31 ESRD patients (18 male and 13 female, mean
age 62±12 years, mean duration of dialysis 6.6±6.6 years).
In 16-slice MSCT, the calciﬁed coronary lesions were found in
24 cases (80%), including 13 cases with severe degree of
calciﬁcation as indicated by the coronary artery calciﬁcation
score (more than 400). However, the serum P level was
45.6mg/dl in 39% of the patients in this sample.3 Therefore,
we examined the relationship between vascular calciﬁcation
and serum P level using the autopsy records of ESRD patients.
We analyzed the autopsy records of 224 ESRD patients (age
53.8±17.0 years, sex (M/F) 158/66, duration of dialysis
3.41±4.59 years). On drawing the receiver operating
characteristic curve, the cut-off point of the P level was
4.8mg/dl (sensitivity 77.8%, speciﬁcity 66.7%) (Figure 1).
This value (4.8mg/dl) was almost the normal P level,
according to the European Best Practice Guidelines. At
present it is possible to use cinacalcet and lanthanum
carbonate, which we were unable to use in 2003 when the
KDOQI Clinical Practice Guidelines were presented, and
control the serum P level easily. So, the targeted value of the P
should be reviewed lower to normal range.
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The Authors Reply: Yokoyama et al.1 take issue with our
recommendation to lower elevated phosphorus levels toward
the normal range in patients with chronic kidney disease
(CKD) stage 5D (2C), as reported in the KDIGO (Kidney
Disease: Improving Global Outcomes) clinical practice
guidelines for the diagnosis, evaluation, prevention, and
treatment of Chronic Kidney Disease-Mineral and Bone
Disorder (CKD-MBD), chapter 4.1.1.2 The strength of this
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Figure 1 |The receiver operating characteristic (ROC) curves of
coronary artery calcification in autopsy samples and serum
phosphorus level in end-stage renal disease (ESRD) patients.
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recommendation has been classiﬁed as ‘2’, meaning that the
majority of people in this situation would want the
recommended course of action, but many would not, and
different choices will be appropriate for different patients. The
quality of the studies used for this recommendation was
classiﬁed as ‘C’, indicating that it was low. This means that the
true effect may be substantially different from the estimate of
the effect.
The authors mention that many studies have shown a close
association between serum phosphorus concentration and the
relative risk of mortality. Based on these observations, and
their data demonstrating an association of vascular calciﬁca-
tion with serum phosphorus concentrations of 4.8mg/dl or
greater, they claim that the serum phosphorus levels should be
normalized in patients with CKD stage 5D. As pointed out in
our CKD-MBD guideline, it is impossible to draw ﬁrm
conclusions from association studies, because they are only
hypothesis generating. There are several examples in recent
literature wherein randomized controlled trials did not
conﬁrm the results of observational studies in patients with
CKD, as for example with anemia correction or cholesterol
lowering.3 It is also not clear whether slowing vascular
calciﬁcation translates into improvements in clinical out-
comes, and therefore this should be considered as a surrogate
end point only and should not supersede conclusions from
associative mortality studies.
To date, there is no convincing report showing that the
active normalization of hyperphosphatemia with any therapy
(phosphate binders, diet, or dialysis) improves hard patient
outcomes such as fractures, cardiovascular events or death.
Thus, although the experimental evidence that phosphorus is
a uremic toxin is strong,4 deﬁnitive human data are lacking.
Therefore, although it is reasonable to lower serum
phosphorus levels towards normal, caregivers must weigh
any potential beneﬁt against the potential adverse conse-
quences of such an approach for a given patient.5
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Proposed controlled trials of
phosphate reduction in CKD:
which whey should we go?
To the Editor: Isakova et al.1 have written an outstanding
review of the potential importance of phosphate as a uremic
toxin in many organ systems, and justiﬁably cite the need for
randomized controlled trials in this area. However, their
proposed trial designs primarily emphasize the testing of various
phosphate binders, with diet being relegated to a secondary role.
Even a hefty dose of binder will remove only about 200–300mg/
day of phosphate,2,3 whereas phosphate intake is commonly in
the range of 1–1.5 g/day, of which about 70% is normally
absorbed. There is some degree of nihilism in this area with
regard to dietary counseling, although compliance with very-
low-protein diets may not be that difﬁcult for a substantial
number of patients.4 Furthermore, phosphate intake can to a
substantial extent be decoupled from protein intake. Murphy-
Gutekunst and Uribarri5 have reviewed the many sources of
industry-added phosphate to foods, including processed meats,
cereals, and soft drinks, and Sherman and Mehta6 have
emphasized the variability of the phosphate to protein ratio.
Boiling of meat can reduce its phosphate content substantially,
while maintaining most of its nitrogen content.7 Finally,
powdered whey protein is a cheap dietary supplement widely
available in health food stores and gymnasiums. Although the
phosphate content of whey varies, a typical composition may be
56mg of phosphate in 25 g (2.24mg/g) of very high biological
value protein (TwinLab 100% Whey Protein Fuel, Ideasphere,
American Fork, UT, USA). Methods for formulating low-
phosphorus whey protein hydrolysates have been described,
which produce a product containing as little as 0.15mg
phosphorus per gram of protein.8 A dose of 50 g/day of protein
supplement as commercially available powdered whey would
deliver only 100–200mg/day of phosphorus. This, coupled with
a 0.3 g/kg/day low-protein diet, with special attention to
avoidance of foods with a high phosphorus/protein ratio, should
be able to reduce the dietary phosphate intake from 1–1.5 g/day
to the range of 500–600mg/day, while maintaining amino-acid
needs. The use of whey protein in uremia is not a new idea,9 but
is one that might bear revisiting in more modern circumstances.
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